Vunakizumab for adults with spondyloarthritis
Part of Bones, joints & muscles clinical trials.
This study tests a new biologic drug called Vunakizumab for people with spondyloarthritis, a type of arthritis that affects the spine and joints. It aims to see if it can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of spondyloarthritis (excluding psoriatic arthritis) and be eligible for biologic therapy.
- You must be willing to follow the study protocol and communicate with the research team.
- You cannot be allergic to the study drug or its ingredients.
- If you are able to have children, you must agree to use highly effective birth control during the study, and for 20 weeks after the last dose.
- You should not have active infections, moderate to severe heart failure, cancer, or certain other inflammatory diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information from people with various rheumatic autoimmune diseases who are using vunakizumab. The goal is to better understand how the medication works in real life, including side effects and how people are doing.
This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.
This study tests a new biologic medicine called vunakizumab for people with moderate to severe plaque psoriasis whose current biologic treatment isn't working well enough. The goal is to see if switching to vunakizumab can improve skin symptoms and is safe.
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
This trial tests a new medicine called vunakizumab for various inflammatory skin diseases like eczema or psoriasis. If you have such a conditionwit, this study may help see how well the treatment works for you.
This trial tests a new medication called vilamakitug to see if it can reduce pain and inflammation in people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It may help those who haven't found relief with other treatments.
Hear when a new Spondyloarthritis (SpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.